

STEP THERAPY POLICY

- POLICY:** Gout Medications Step Therapy Policy
- Uloric® (febuxostat tablets – Takeda, generic)
 - Zyloprim® (allopurinol tablets – Casper, generic)

REVIEW DATE: 01/17/2024

OVERVIEW

Allopurinol (Zyloprim, generic), a xanthine oxidase inhibitor, is indicated for the following uses:¹

- **Signs and symptoms of primary or secondary gout** (e.g., acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) in adults.
- **Cancer therapy which causes elevations of serum and urinary uric acid levels**, in adult and pediatric patients with leukemia, lymphoma, and malignancies.
- **Recurrent calcium oxalate calculi**, in adults whose daily uric acid excretion exceeds 800 mg/day for male patients and 750 mg/day for female patients.

Febuxostat (Uloric, generic), a xanthine oxidase inhibitor, is indicated for the **chronic management of hyperuricemia in adults with gout** who have had an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.²

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: allopurinol tablets (Zyloprim, generic)

Step 2: febuxostat tablets (Uloric, generic)

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. If the patient is receiving concomitant medications that have significant drug-drug interactions with the Step 1 Product, which are not noted with Uloric/febuxostat tablets (e.g., cyclosporine, chlorpropamide), approve the Step 2 Product.
3. No other exceptions are recommended.

01/17/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

REFERENCES

1. Zyloprim® tablets [prescribing information]. East Brunswick, NJ: Casper; October 2023.
2. Uloric® tablets [prescribing information]. Lexington, MA: Takeda; April 2023.